PRIDE syndrome

Bhanja, Dibyendu Bikash; Sil, Abheek; Punithakumar, Esther J; Panigrahi, Avik; Das, Avijit; Biswas, Surajit Kumar

doi:10.1136/postgradmedj-2020-137939

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most cases reported thinning or loss of scalp hair, one report documented unexpected regrowth of hair over bald scalp [11]. It has been postulated that hypertrichosis could be due to EGFRI-induced failure of anagen to catagen switch resulting in increased terminal differentiation of epithelial cells of hair follicles [12]. Even though this mechanism explains elongation of hair, the reasons for localized involvement, and loss of scalp hair seen in other reports (table 1) are still not known.…”

Section: Opis Przypadkumentioning

confidence: 98%

“…Stwierdza się, że nadmierny wzrost owłosienia może być spowodowany wstrzymaniem przez inhibitory EGFR przechodzenia włosów z fazy anagenu w katagen. Skutkuje to zwiększonym różnicowaniem terminalnym komórek nabłonka mieszków włosowych [12]. Jeśli nawet mechanizm ten wyjaśnia wydłużanie włosów, przyczyny ogniskowej lokalizacji tego procesu, a także utraty włosów na skórze głowy obserwowanej u pacjentów w innych doniesieniach (tab.…”

Section: Conflict Of Interestunclassified

See 1 more Smart Citation

PRIDE syndrome with lumbosacral hypertrichosis

Naaz¹,

Khan²,

Amin³

et al. 2022

View full text Add to dashboard Cite

Introduction:The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, Dryness due to EGFR inhibition) syndrome is a cutaneous adverse effect of EGFR inhibitors. Case report: We describe an 80-year-old man, who presented with itchy papules over the suprapubic region and hair growth over the lower back for 1 month. He was diagnosed with squamous cell carcinoma of the lung, and was treated with oral gefitinib 250 mg daily for 4 months. Cutaneous examination revealed generalized xerosis, discrete papules and pustules with overlying yellow crusts over the suprapubic region, and paronychia with dystrophic changes over the right first and third toe nail. Localised hypertrichosis was seen over the back in midline lumbosacral region. Conclusions: Hair overgrowth such as trichomegaly and hypertrichosis have been described in the PRIDE syndrome. We describe an atypical presentation of the syndrome with lumbosacral hypertrichosis.

show abstract

Section: Opis Przypadkumentioning

confidence: 98%

Section: Conflict Of Interestunclassified

PRIDE syndrome with lumbosacral hypertrichosis

Naaz¹,

Khan²,

Amin³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Z uwagi na działanie celowane są one pozbawione poważnych ogólnoustrojowych działań niepożądanych, jak to ma miejsce w przypadku klasycznych chemioterapeutyków, jednak wykazują działanie niepożądane związane z ekspresją EGFR w komórkach naskórka, gruczołów łojowych i nabłonku mieszków włosowych [3]. Najczęstsze działania niepożądane EGFRI, czyli osutka grudkowo-krostkowa, paronychia, nieprawidłowości regulacji wzrostu włosów, świąd i suchość, zostały zebrane w akronim PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to EGFR inhibitors) [4].…”

Section: Wprowadzenieunclassified

“…Due to their targeted action, they are devoid of serious systemic side effects, as is the case with classic chemotherapeutic agents, but they show side effects related to the expression of EGFR in the cells of the epidermis, sebaceous glands or hair follicle epithelium [3]. The most common side effects of EGFRI, i.e., papulopustular rash, paronychia, abnormalities of hair growth regulation, pruritus and dryness have been collected under the acronym PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to EGFR inhibitors) [4].…”

Section: Opis Przypadkumentioning

confidence: 99%

PRIDE syndrome associated with panitumumab treatment – case report and literature review

Pałdyna¹,

Rutkowska²,

Biało-Wójcicka³

2023

View full text Add to dashboard Cite

Introduction: Epidermal growth factor receptor inhibitors, including panitumumab, are drugs with a proven effect on overal survival of patients with advanced colorectal cancer. They have a better safety profile compared to classic cytotoxic drugs, but they may have side effects resulting directly from the drug's mechanism of action. Case report: A 64-year-old man, treated palliatively with panitumumab for cancer of the sigmoido-rectal junction, was admitted to the Dermatology Department with disseminated maculopustular rash on the scalp and upper trunk. Also, layered yellowish crusts were present on the face and scalp. Edema and erythema were visible in the lateral folds of the nails of the hands and feet. The diagnosis of panitumumab -induced PRIDE syndrome (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors). Laboratory tests showed hypomagnesemia, hyperglycemia and elevated glycated hemoglobin values. Doxycycline and systemic glucocorticosteroids were introduced with improvement. Conclusions: Early diagnosis of the cutaneous adverse effects oncological treatment and initiation of treatment contributes to the improvement of the quality of life of patients and the continuation of oncological therapy.

show abstract

Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review

Das

Sil

Khan

et al. 2023

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) target the signal transduction pathways of protein kinases by several modes of inhibition. Adverse effects are generally dose-dependent, with certain side effects unique to each drug. However, due to similarities in target sites, different classes of TKIs may have identical or overlapping side effect profiles. This narrative review is an attempt to summarize the common and uncommon adverse effects of different classes of tyrosine kinase inhibitors.

show abstract

PRIDE syndrome

Cited by 4 publications

References 5 publications

PRIDE syndrome with lumbosacral hypertrichosis

PRIDE syndrome with lumbosacral hypertrichosis

PRIDE syndrome associated with panitumumab treatment – case report and literature review

Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review

Contact Info

Product

Resources

About